Neuroprotective effect of intravitreal triamcinolone acetonide against photoreceptor apoptosis in a rabbit model of subretinal hemorrhage

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 9, 2008, Pages 4071-4077

  Bhisitkul, Robert B ^a   Winn, Bryan J ^a   Lee, On Tat ^a   Wong, Joshua ^a   Pereira, Daniel De Souza ^a   Porco, Travis C ^a   He, Xining ^b   Hahn, Paul ^b   Dunaief, Joshua L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRON; TRIAMCINOLONE ACETONIDE; NEUROPROTECTIVE AGENT; PROPOXYCAINE; PROXYMETACAINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD AUTOTRANSFUSION; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL RABBIT; EYE TOXICITY; FEMALE; FLUORESCENCE MICROSCOPY; HISTOPATHOLOGY; IRON TRANSPORT; MACROPHAGE; MORPHOMETRICS; NEUROPROTECTION; NICK END LABELING; NONHUMAN; PATHOGENESIS; PHOTORECEPTOR CELL; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA HEMORRHAGE; RETINA INJURY; RETINOTOXICITY; ANIMAL; DISEASE MODEL; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHOTORECEPTOR; PHYSIOLOGY; PUPIL; RABBIT; VITREOUS BODY;

ANIMALS; APOPTOSIS; DISEASE MODELS, ANIMAL; FEMALE; IRON; NEUROPROTECTIVE AGENTS; PHOTORECEPTORS; PROPOXYCAINE; PUPIL; RABBITS; RETINAL HEMORRHAGE; TRIAMCINOLONE ACETONIDE; VITREOUS BODY;

EID: 53149107878     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-1892     Document Type: Article

References (52)

1. Glatt H, Machemer R. Experimental subretinal hemorrhage in rabbits. Am J Ophthalmol. 1982;94:762-773.
2. Toth CA, Morse LS, Hjelmeland LM, Landers MB 3rd. Fibrin directs early retinal damage after experimental subretinal hemorrhage. Arch Ophthalmol. 1991;109:723-729.
3. Benner JD, Hay A, Landers MB, Hjelmeland LM, Morse LS. Fibrinolytic-assisted removal of experimental subretinal hemorrhage within 7 days reduces outer retinal degeneration. Ophthalmology. 1994;101:672-681. (Pubitemid 24113227)
4. Bressler NM, Bressler SB, Childs AL, et al. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13. Ophthalmology. 2004;111:1993-2006. (Pubitemid 39446716)
5. Grossniklaus HE, Wilson DJ, Bressler SB, et al. Clinicopathologic studies of eyes that were obtained postmortem from four patients who were enrolled in the submacular surgery trials: SST Report No. 16. Am J Ophthalmol. 2006;141:93-104.
6. Toth CA, Benner JD, Hjelmeland LM, Landers MBD, Morse LS. Ultramicrosurgical removal of subretinal hemorrhage in cats. Am J Ophthalmol. 1992;113:175-182.
7. Hochman MA, Seery CM, Zarbin MA. Pathophysiology and management of subretinal hemorrhage. Surv Ophthalmol. 1997;42:195-213.
8. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
9. Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431. (Pubitemid 44511557)
10. Brown DM, Kaiser PK, Michels M, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444. (Pubitemid 44511558)
11. Dentchev T, Hahn P, Dunaief JL. Strong labeling for iron and the iron-handling proteins ferritin and ferroportin in the photoreceptor layer in age-related macular degeneration. Arch Ophthalmol. 2005;123:1745-1746. (Pubitemid 41785113)
12. West BT, Welch KB, Galecki AT. Linear Mixed Models: A Practical Guide Using Statistical Software. Boca Raton, FL: Chapman and Hall/CRC; 2007.
13. Yu SY, Damico FM, Viola F, D'Amico DJ, Young LH. Retinal toxicity of intravitreal triamcinolone acetonide: a morphological study. Retina. 2006;26:531-536. (Pubitemid 44620394)
14. Hao W, Wenzel A, Obin MS, et al. Evidence for two apoptotic pathways in light-induced retinal degeneration. Nat Genet. 2002;32:254-260.
15. Dunaief JL, Dentchev T, Ying GS, Milam AH. The role of apoptosis in age-related macular degeneration. Arch Ophthalmol. 2002;120:1435-1442. (Pubitemid 36406417)
16. She H, Nakazawa T, Matsubara A, et al. Reduced photoreceptor damage after photodynamic therapy through blockade of nitric oxide synthase in a model of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2007;48:2268-2277. (Pubitemid 351261305)
17. Zacks DN, Hänninen V, Pantcheva M, et al. Caspase activation in an experimental model of retinal detachment. Invest Ophthalmol Vis Sci. 2003;44:1262-1267. (Pubitemid 36297848)
18. Arroyo JG, Yang L, Bula D, Chen DF. Photoreceptor apoptosis in human retinal detachment. Am J Ophthalmol. 2005;139:605-610.
19. He X, Hahn P, Iacovelli J, et al. Iron homeostasis and toxicity in retinal degeneration. Prog Retin Eye Res. 2007;26:649-673. (Pubitemid 47615564)
20. Paskowitz DM, Nune G, Yasumura D, et al. BDNF reduces the retinal toxicity of verteporfin photodynamic therapy. Invest Ophthalmol Vis Sci. 2004;45:4190-4196. (Pubitemid 39411179)
21. Sun X, Xu X, Wang F, et al. Effects of nerve growth factor for retinal cell survival in experimental retinal detachment. Curr Eye Res. 2007;32:765-772. (Pubitemid 47450622)
22. Zacks DN, Boehlke C, Richards AL, Zheng QD. Role of the Fas-signaling pathway in photoreceptor neuroprotection. Arch Ophthalmol. 2007;125:1389-1395. (Pubitemid 47606606)
23. Gould E, Woolley CS, McEwen BS. Short term glucocorticoid manipulations affect neuronal morphology and survival in the adult dentate gyrus. Neuroscience. 1990;37:367-375. (Pubitemid 20268190)
24. Messmer UK, Winkel G, Briner VA, Pfeilschifter J. Suppression of apoptosis by glucocorticoids in glomerular endothelial cells: effects on proapoptotic pathways. Br J Pharmacol. 2000;129:1673-1683. (Pubitemid 30219010)
25. Messmer UK, Pereda-Fernandez C, Manderscheid M, Pfeilschifter J. Dexamethasone inhibits TNF-alpha-induced apoptosis and IAP protein downregulation in MCF-7 cells. Br J Pharmacol. 2001;133:467-476. (Pubitemid 32591912)
26. Nichols NR, Agolley D, Zieba M, Bye N. Glucocorticoid regulation of glial responses during hippocampal neurodegeneration and regeneration. Brain Res Rev. 2005;48:287-301. (Pubitemid 40585760)
27. Psarra AG, Bochaton-Piallat M-L, Gabbiani G, Sekeris CE, Tsacopoulos M. Mitochondrial localization of glucocortocoid receptor in glial (Muller) cells in the salamander retina. Glia. 2003;41:38-49. (Pubitemid 36164283)
28. Wenzel A, Grimm C, Seeliger MW, et al. Prevention of photoreceptor apoptosis by activation of the glucocorticoid receptor. Invest Ophthalmol Vis Sci. 2001;42:1653-1659. (Pubitemid 32520761)
29. Rosner M, Lam TT, Fu J, Tso MO. Methylprednisolone ameliorates retinal photic injury in rats. Arch Ophthalmol. 1992;110:857-861. (Pubitemid 126824650)
30. Fu J, Lam TT, Tso MO. Dexamethasone ameliorates retinal photic injury in albino rats. Exp Eye Res. 1992;54:583-594.
31. Abraham IM, Harkany T, Horvath KM, Luiten PGM. Action of glucocorticoids on survival of nerve cells: promoting neurodegeneration or neuroprotection? J Neuroendocrinol. 2001;13:749-760. (Pubitemid 32894429)
32. Bracken MB, Shepard MJ, Collins WF, et al. A randomized controlled trial of methylprednisolone or naloxone in the treatment of acute spinal cord injury. N Engl J Med. 1990;322:1405-1411.
33. Bracken MB, Shepard MJ, Holford TR, et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury: results of the third national acute spinal cord injury randomized controlled trial. JAMA. 1997;277:1597-1604.
34. deGans J, van de Beek D, European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators. Dexamethasone in adults with bacterial meningitis. N Engl J Med. 2002;347:1549-1556.
35. Chaudhuri A. Adjunctive dexamethasone treatment in acute bacterial meningitis. Lancet Neurol. 2004;3:54-62. (Pubitemid 38018928)
36. Tuor UI. Glucocorticoids and the prevention of hypoxic-ischemic brain damage. Neurosci Biobehav Rev. 1997;21:175-179. (Pubitemid 27102562)
37. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2005;112:301-304. (Pubitemid 40202568)
38. Ruiz-Moreno JM, Montero JA, Zarbin MA. Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 2-year outcome. Retina. 2007;27:458-461. (Pubitemid 46624286)
39. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina. 2007;27:133-140. (Pubitemid 46245638)
40. Heier JS, Boyer DS, Ciulla TA, et al. FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol. 2006;124:1532-1542.
41. Bressler N, Bressler S, Fine S. Age related macular degeneration. Surv Ophthalmol. 1988;32:375-413.
42. Ibanez HE, Williams DF, Thomas MA, et al. Surgical management of submacular hemorrhage: a series of 47 consecutive cases. Arch Ophthalmol. 1995;113:62-69.
43. Avery RI, Fekrat S, Hawkins BS, et al. Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. Retina. 1996;16:183-189. (Pubitemid 26190846)
44. Berrocal MH, Lewis ML, Flynn HW Jr. Variations in the clinical course of submacular hemorrhage. Am J Ophthalmol. 1996;122:486-493.
45. Scupola A, Coscas G, Soubrane G, et al. Natural history of macular subretinal hemorrhage in age-related macular degeneration. Ophthalmologica. 1999;213:97-102. (Pubitemid 29049394)
46. DeJuan E Jr, Machemer R. Vitreous surgery for hemorrhagic and fibrous complications of age-related macular degeneration. Am J Ophthalmol. 1988;105:25-29. (Pubitemid 18021339)
47. Haupert CL, McCuen BW II, Jaffe GJ, et al. Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration. Am J Ophthalmol. 2001;131:208-215.
48. Thompson JT, Sjaarda RN. Vitrectomy for the treatment of submacular hemorrhages from macular degeneration: a comparison of submacular hemorrhages/membrane removal and submacular tissue plasminogen activator-assisted pneumatic displacement. Trans Am Ophthalmol Soc. 2005;103:98-106.
49. Hassan AS, Johnson MW, Schneiderman TE, et al. Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement. Ophthalmology. 1999;106:1900-1906.
50. Chen CY, Hooper C, Chiu D, et al. Management of submacular hemorrhage with intravitreal injection of tissue plasminogen activator and expansile gas. Retina. 2007;27:321-328. (Pubitemid 46398897)
51. Hasler PW, la Cour M, Villumsen J. Pneumatic displacement and intravitreal bevacizumab in the management of subretinal haemorrhage caused by choroidal neovascularization. Acta Ophthalmol Scand. 2007;85:577-579. (Pubitemid 47163127)
52. Lüke M, Januschowski K, Warga M, et al. The retinal tolerance to bevacizumab in co-application with a recombinant tissue plasminogen activator. Br J Ophthalmol. 2007;91:1077-1082. (Pubitemid 47122118)